ADPRS and ovarian carcinoma: As already shown in U2OS cells, ARH3 KO diminished the sensitivity of the ovarian cancer cell lines to the PARPi olaparib (Fig. 1C-F, left panels, and Figs. S1A, S1C, S1E, S1G).